Innoviva, Inc.

Healthcare · Biotechnology · United States

Last price 21.31 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.54B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use ...